NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.18 -2.75 (-3.36%) GOLD FUTURES
2,330.20 +27.30 (+1.19%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,806.31 -2,112.36 (-4.41%)
Agenus Inc. (AGEN)
After hours:
- Business Wire
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
LEXINGTON, Mass., May 01, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30, 2024, that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2). Accordingly, the Company now satisfies all requirements for continued listing on the NASDAQ Capital Market and the matter is now closed.
- Business Wire
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
LEXINGTON, Mass., April 24, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced an upcoming presentation from the Phase 1b trial of botensilimab in combination with balstilimab ("BOT/BAL") in patients with relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM) will be presented at the upcoming American Society of Clinical Oncology (ASCO) Meeting, to be held
- Business Wire
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
LEXINGTON, Mass., April 23, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
